<div id="readability-page-1"><p>J.P. Morgan analyst Brian Cheng maintained a Sell rating on Intellia Therapeutics yesterday and set a price target of $8.00. The company’s shares closed yesterday at $14.28.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>According to TipRanks, Cheng is a 4-star analyst with an average return of <span>6.7%</span> and a 52.55% success rate. Cheng covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, Revolution Medicines, and Protara Therapeutics.</p> <p>In addition to J.P. Morgan, Intellia Therapeutics also received a Sell from Goldman Sachs’s Salveen Richter in a report issued on May 11. However, yesterday, Morgan Stanley maintained a Hold rating on Intellia Therapeutics (NASDAQ: NTLA).</p></div>

NTLA

IBBQ

LABU

<p>J.P. Morgan analyst Brian Cheng has maintained a Sell rating on Intellia Therapeutics (NTLA) with a price target of $8.00, while the shares closed at $14.28. Cheng, a 4-star analyst, has an average return of 6.7% and a 52.55% success rate. Goldman Sachs also issued a Sell rating on Intellia, while Morgan Stanley maintained a Hold rating.</p>

Tip Ranks

Intellia Therap

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

Franklin Genomic Adv ETF

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

Wisdomtree BioRevolution Fund ETF

Ark Genomic Revolution ETF

iShares Genomics Immunology and Healthcare ETF

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

JPMorgan Chase

Protagonist Therap

Revolution Medicines

Protara Therapeutic

Goldman Sachs

Morgan Stanley

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM)

GS Hldg R

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

J.P. Morgan Remains a Sell on Intellia Therapeutics (NTLA)